<DOC>
	<DOCNO>NCT01580891</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety test formulation Naftifine HCl Cream 1 % ( Taro Pharmaceuticals Inc. ) compare already market formulation Naftin® ( Naftifine HCl ) 1 % Cream ( Merz Pharmaceuticals ) placebo patient tinea pedis show superiority active treatment placebo dose day 28 day .</brief_summary>
	<brief_title>Evaluate Clinical Equivalence Two Naftifine HCl 1 % Creams Patients With Interdigital Tinea Pedis</brief_title>
	<detailed_description />
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<mesh_term>Naftifine</mesh_term>
	<criteria>Male nonpregnant , nonlactating female 18 year age old . Signed informed consent form , meet criteria current FDA regulation . If female childbearing potential , negative urine pregnancy test baseline visit , prepare abstain sexual intercourse use reliable method contraception study . A total score least 4 clinical sign symptom tinea pedis target lesion . In addition , infected area must minimum score least 2 erythema minimum score least 2 scaling . A confirmed clinical diagnosis tinea pedis lesion localize interdigital space predominantly interdigital , may extend area foot . The presence tinea pedis infection , confirm observation segment fungal hypha microscopic 10 % potassium hydroxide wet mount examination . Females pregnant , lactate likely become pregnant study . Use antipruritic , include antihistamine within 72 hour prior baseline visit . Use topical corticosteroid , antibiotic antifungal therapy within 2 week prior baseline visit . Use systemic corticosteroid , antibiotic antifungal therapy within 1 month prior baseline visit . Use oral terbinafine itraconazole within 2 month prior baseline visit . Use immunosuppressive medication radiation therapy within 3 month prior baseline visit . Any known hypersensitivity Naftifine HCl , component formulation antifungal agent . Confluent , diffuse moccasintype tinea pedis entire plantar surface . Significant history current evidence chronic infectious disease , system disorder , organ disorder , medical condition would place patient undue risk participation could jeopardize integrity study evaluation . Evidence concurrent dermatophytic infection toe nail dermatological condition foot may interfere evaluation tinea pedis . Patients past history tinea pedis infection lack response antifungal therapy . Patients would noncompliant requirement study protocol . Participation research study within 30 day prior baseline visit . Employees family member employee research center investigator . Previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Naftifine HCl Cream 1 %</keyword>
	<keyword>Naftin® ( Naftifine HCl ) Cream 1 %</keyword>
	<keyword>Tinea Pedis</keyword>
	<keyword>Efficacy safety</keyword>
</DOC>